Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
暂无分享,去创建一个
Ling Tian | Francisco Vega | G. Rassidakis | L. Medeiros | L. Tian | F. Claret | F. Vega | J. H. Cho-Vega | L Jeffrey Medeiros | L. Medeiros | Jeong Hee Cho-Vega | Vasiliki Leventaki | Coralyn Atwell | Francois-Xavier Claret | George Z Rassidakis | V. Leventaki | Coralyn Atwell | J. Cho-Vega | Vasiliki Leventaki
[1] T. McDonnell,et al. Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. , 2002, American Journal of Clinical Pathology.
[2] M. Wasik,et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. , 2001, Cancer research.
[3] M. Torbenson,et al. mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms , 2004, Clinical Cancer Research.
[4] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[5] P. Houghton,et al. Arrest and Determine the Cellular Response to Rapamycin 1 Cooperate in Enforcing Rapamycin-induced G CIP 1 p 53 / p 21 Updated , 2001 .
[6] J. Avruch,et al. Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.
[7] T. Harris,et al. TOR Signaling , 2003, Science's STKE.
[8] Stefano Fumagalli,et al. Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase , 1998, The EMBO journal.
[9] Robert T. Abraham,et al. Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 Is Mediated by p70S6 Kinase* , 2005, Journal of Biological Chemistry.
[10] M. Mann,et al. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[11] S. Morris,et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. , 2000, Blood.
[12] Christine C. Hudson,et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. , 2000, Cancer research.
[13] S. Bodine,et al. Control of Ser2448 Phosphorylation in the Mammalian Target of Rapamycin by Insulin and Skeletal Muscle Load* , 2002, The Journal of Biological Chemistry.
[14] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[15] J. Blenis,et al. Identification of S6 Kinase 1 as a Novel Mammalian Target of Rapamycin (mTOR)-phosphorylating Kinase* , 2005, Journal of Biological Chemistry.
[16] A. Gingras,et al. The mRNA 5' cap-binding protein eIF4E and control of cell growth. , 1998, Current opinion in cell biology.
[17] J. Blenis,et al. TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function , 2003, Current Biology.
[18] S. Sehgal,et al. Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.
[19] S. Morris,et al. Translocations involving anaplastic lymphoma kinase (ALK) , 2001, Oncogene.
[20] J. Douros,et al. New antitumor substances of natural origin. , 1981, Cancer treatment reviews.
[21] D. Sabatini,et al. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.
[22] S. Lowe,et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.
[23] S. Schreiber,et al. Erratum: Control of p70 S6 kinase by kinase activity of FRAP in vivo (Nature (1995) 377 (441-446)) , 1995 .
[24] B. Woda,et al. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. , 1999, The American journal of pathology.
[25] L. Bowman,et al. Insulin stimulates the translation of ribosomal proteins and the transcription of rDNA in mouse myoblasts. , 1988, The Journal of biological chemistry.
[26] J. Avruch,et al. Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.
[27] G. Rassidakis,et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. , 2005, Blood.
[28] J. Crespo,et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.
[29] T. McDonnell,et al. Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma , 2003 .
[30] N. Sonenberg,et al. Ras mediates translation initiation factor 4E-induced malignant transformation. , 1992, Genes & development.
[31] J. Chen,et al. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Schreiber,et al. Control of p70 S6 kinase by kinase activity of FRAP in vivo , 1995, Nature.
[33] J. Testa,et al. Cell Cycle Withdrawal Promotes Myogenic Induction of Akt, a Positive Modulator of Myocyte Survival , 1999, Molecular and Cellular Biology.
[34] M. Polymenis,et al. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc , 1996, Molecular and cellular biology.
[35] T. McDonnell,et al. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] Tobias Schmelzle,et al. TOR, a Central Controller of Cell Growth , 2000, Cell.
[37] R. Fonseca,et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Jennifer Skeen,et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. , 2003, Genes & development.
[39] N. Sonenberg,et al. Cell cycle-dependent translational control , 2000 .
[40] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[41] M. Bjornsti,et al. The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.
[42] V. Brown,et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[43] S. Snyder,et al. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[44] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[45] J. Blenis,et al. Identification of a Conserved Motif Required for mTOR Signaling , 2002, Current Biology.
[46] O. Meyuhas. Synthesis of the translational apparatus is regulated at the translational level. , 2000, European journal of biochemistry.
[47] I. Mellinghoff,et al. AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression* , 2004, Journal of Biological Chemistry.
[48] G. Thomas,et al. The modular phosphorylation and activation of p70s6k , 1997, FEBS letters.